NCT03521193View on ClinicalTrials.gov

pLatelEts And MigRaine iN patEnt foRamen Ovale

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Platelet Aggregation, SpontaneousMigraine With AuraPatent Foramen Ovale
Interventions
DEVICE

patent foramen ovale closure

Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment

Trial Locations (1)

20138

Centro Cardiologico Monzino, IRCCS, Milan

All Listed Sponsors
lead

Centro Cardiologico Monzino

OTHER

NCT03521193 - pLatelEts And MigRaine iN patEnt foRamen Ovale | Biotech Hunter | Biotech Hunter